drugset / Trial / NCT06500208
Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC
NaSingle-groupOpen-labelTreatment
Summary
Investigators plan to conduct a single-arm clinical study of adebelimab, a novel PD-L1 inhibitor, in the neoadjuvant treatment of early or locally advanced high-risk ER+/HER2- breast cancer, to explore whether the addition of immune checkpoint inhibitors to traditional neoadjuvant chemotherapy can improve the pathologic complete response rate (pCR) of patients, evaluate its therapeutic safety, and further analyze the biomarkers of the efficacy of neoadjuvant immunotherapy for ER+/HER2- breast cancer, so as to support the clinical application of the drug.
Timeline
- Start
- 2024-11-01
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 600 mg/m2 | — |
| Subject | Epirubicin | Small molecule | 90 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 100 mg/m2 | — |